<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: Risk Factors ", fill: "#d9004c"},
{source: "1: Risk Factors ", target: "1: risks described", fill: "#d9004c"},
{source: "1: risks described", target: "1: Edwards Lifesciences ", fill: "#d9004c"},
{source: "1: Edwards Lifesciences ", target: "1: filings with", fill: "#d9004c"},
{source: "1: filings with", target: "1: Securities and Exchange Commission", fill: "#d9004c"},
{source: "1: Risk Factors ", target: "5: cardiovascular products industry", fill: "#e62020"},
{source: "5: cardiovascular products industry", target: "5: characterized by rapid", fill: "#e62020"},
{source: "5: characterized by rapid", target: "5: technological", fill: "#e62020"},
{source: "5: technological", target: "5: frequent new product introductions", fill: "#e62020"},
{source: "5: frequent new product introductions", target: "5: industry standards", fill: "#e62020"},
{source: "5: cardiovascular products industry", target: "10: addition even", fill: "#f400a1"},
{source: "10: addition even", target: "10: Edwards Lifesciences ", fill: "#f400a1"},
{source: "10: Edwards Lifesciences ", target: "10: successfully", fill: "#f400a1"},
{source: "10: successfully", target: "10: enhancements", fill: "#f400a1"},
{source: "10: enhancements", target: "10: generations", fill: "#f400a1"},
{source: "10: generations", target: "10: products may", fill: "#f400a1"},
{source: "10: products may", target: "10: development", fill: "#f400a1"},
{source: "10: development", target: "10: obsolete by", fill: "#f400a1"},
{source: "10: obsolete by", target: "10: preferences", fill: "#f400a1"},
{source: "10: preferences", target: "10: introduction by", fill: "#f400a1"},
{source: "10: introduction by", target: "10: competitors", fill: "#f400a1"},
{source: "10: competitors", target: "10: products embodying new technologies", fill: "#f400a1"},
{source: "10: addition even", target: "12: Edwards Lifesciences ", fill: "#79443b"},
{source: "12: Edwards Lifesciences ", target: "12: potential product", fill: "#79443b"},
{source: "12: potential product", target: "12: liability risks", fill: "#79443b"},
{source: "12: liability risks", target: "12: design manufacture", fill: "#79443b"},
{source: "12: Edwards Lifesciences ", target: "14: medical devices manufactured", fill: "#e6e6fa"},
{source: "14: medical devices manufactured", target: "14: long periods", fill: "#e6e6fa"},
{source: "14: medical devices manufactured", target: "22: Edwards Lifesciences ", fill: "#00bfff"},
{source: "22: Edwards Lifesciences ", target: "22: purchases certain supplies from single sources", fill: "#00bfff"},
{source: "22: purchases certain supplies from single sources", target: "22: constraints", fill: "#00bfff"},
{source: "22: constraints", target: "22: from regulatory requirements", fill: "#00bfff"},
{source: "22: Edwards Lifesciences ", target: "34: At December ", fill: "#674846"},
{source: "34: At December ", target: "34: Edwards Lifesciences ", fill: "#674846"},
{source: "34: Edwards Lifesciences ", target: "34: equity instruments", fill: "#674846"},
{source: "34: equity instruments", target: "34: recorded unrealized losses", fill: "#674846"},
{source: "34: recorded unrealized losses", target: "34: investments on", fill: "#674846"},
{source: "34: investments on", target: "34: balance sheet", fill: "#674846"},
{source: "34: balance sheet", target: "34: Accumulated Other Comprehensive Income Loss ", fill: "#674846"},
{source: "34: At December ", target: "41: Edwards Lifesciences ", fill: "#f984ef"},
{source: "41: Edwards Lifesciences ", target: "41: successfully", fill: "#f984ef"},
{source: "41: successfully", target: "41: acquisitions", fill: "#f984ef"},
{source: "41: acquisitions", target: "41: strategic alliances on", fill: "#f984ef"},
{source: "41: strategic alliances on", target: "41: such acquisitions could", fill: "#f984ef"},
{source: "41: such acquisitions could", target: "41: difficulties", fill: "#f984ef"},
{source: "41: difficulties", target: "41: expenditures", fill: "#f984ef"},
{source: "41: expenditures", target: "41: significant", fill: "#f984ef"},
{source: "41: significant", target: "41: management", fill: "#f984ef"},
{source: "41: management", target: "41: significant charges", fill: "#f984ef"},
{source: "41: Edwards Lifesciences ", target: "52: Edwards Lifesciences ", fill: "#ffc40c"},
{source: "52: Edwards Lifesciences ", target: "52: economic political", fill: "#ffc40c"},
{source: "52: economic political", target: "52: risks associated with international sales", fill: "#ffc40c"},
{source: "52: risks associated with international sales", target: "52: operations", fill: "#ffc40c"},
{source: "52: Edwards Lifesciences ", target: "54: Edwards Lifesciences ", fill: "#c5b358"},
{source: "54: Edwards Lifesciences ", target: "54: net sales originating", fill: "#c5b358"},
{source: "54: net sales originating", target: "54: United States ", fill: "#c5b358"},
{source: "54: United States ", target: "54: total net sales", fill: "#c5b358"},
{source: "54: Edwards Lifesciences ", target: "56: Edwards Lifesciences ", fill: "#00fa9a"},
{source: "56: Edwards Lifesciences ", target: "56: manufacturing facilities", fill: "#00fa9a"},
{source: "56: manufacturing facilities", target: "56: located outside", fill: "#00fa9a"},
{source: "56: located outside", target: "56: United States", fill: "#00fa9a"},
{source: "56: Edwards Lifesciences ", target: "58: harmed by", fill: "#f88379"},
{source: "58: harmed by", target: "58: foreign medical reimbursement policies", fill: "#f88379"},
{source: "58: foreign medical reimbursement policies", target: "58: foreign regulatory requirements", fill: "#f88379"},
{source: "58: foreign regulatory requirements", target: "58: requirements", fill: "#f88379"},
{source: "58: requirements", target: "58: foreign currency exchange rates", fill: "#f88379"},
{source: "58: foreign currency exchange rates", target: "58: economic conditions particularly", fill: "#f88379"},
{source: "58: economic conditions particularly", target: "58: emerging regions", fill: "#f88379"},
{source: "58: emerging regions", target: "58: export licensing", fill: "#f88379"},
{source: "58: export licensing", target: "58: potentially negative consequences from", fill: "#f88379"},
{source: "58: potentially negative consequences from", target: "58: difficulty", fill: "#f88379"},
{source: "58: difficulty", target: "58: managing foreign operations", fill: "#f88379"},
{source: "58: managing foreign operations", target: "58: life threatening communicable disease", fill: "#f88379"},
{source: "58: life threatening communicable disease", target: "58: international political", fill: "#f88379"},
{source: "58: international political", target: "58: differing labor regulations", fill: "#f88379"},
{source: "58: differing labor regulations", target: "58: differing protection", fill: "#f88379"},
{source: "58: differing protection", target: "58: intellectual property", fill: "#f88379"},
{source: "58: harmed by", target: "66: Edwards Lifesciences ", fill: "#002e63"},
{source: "66: Edwards Lifesciences ", target: "66: manage currency", fill: "#002e63"},
{source: "66: manage currency", target: "66: exchange rate risks", fill: "#002e63"},
{source: "66: exchange rate risks", target: "66: appropriate tradeoff between risk opportunity", fill: "#002e63"},
{source: "66: appropriate tradeoff between risk opportunity", target: "66: cost however", fill: "#002e63"},
{source: "66: cost however", target: "66: completely eliminate", fill: "#002e63"},
{source: "66: completely eliminate", target: "66: exchange rate fluctuations", fill: "#002e63"},
{source: "66: Edwards Lifesciences ", target: "69: interest rates", fill: "#dbd7d2"},
{source: "69: interest rates", target: "69: economy could", fill: "#dbd7d2"},
{source: "69: economy could", target: "69: Edwards Lifesciences ", fill: "#dbd7d2"},
{source: "69: Edwards Lifesciences ", target: "69: borrowing costs", fill: "#dbd7d2"},
{source: "69: borrowing costs", target: "69: financings as well as under", fill: "#dbd7d2"},
{source: "69: financings as well as under", target: "69: existing debt", fill: "#dbd7d2"},
{source: "69: existing debt", target: "69: bears interest", fill: "#dbd7d2"},
{source: "69: bears interest", target: "69: floating rate", fill: "#dbd7d2"},
{source: "69: floating rate", target: "69: which interest rate swaps", fill: "#dbd7d2"},
{source: "69: which interest rate swaps", target: "69: could otherwise restrict", fill: "#dbd7d2"},
{source: "69: interest rates", target: "73: could disproportionately affect", fill: "#f0e68c"},
{source: "73: could disproportionately affect", target: "73: Edwards Lifesciences ", fill: "#f0e68c"},
{source: "73: Edwards Lifesciences ", target: "73: common stock may fall", fill: "#f0e68c"},
{source: "73: could disproportionately affect", target: "74: could affect quarterly", fill: "#23297a"},
{source: "74: could affect quarterly", target: "74: clinical acceptance", fill: "#23297a"},
{source: "74: clinical acceptance", target: "74: customer contracts particularly", fill: "#23297a"},
{source: "74: customer contracts particularly", target: "74: materially", fill: "#23297a"},
{source: "74: materially", target: "74: given quarter", fill: "#23297a"},
{source: "74: given quarter", target: "74: introduction", fill: "#23297a"},
{source: "74: introduction", target: "74: foreign currency exchange rates", fill: "#23297a"},
{source: "74: foreign currency exchange rates", target: "74: unanticipated delays", fill: "#23297a"},
{source: "74: unanticipated delays", target: "74: introducing new products", fill: "#23297a"},
{source: "74: introducing new products", target: "74: competitors apos", fill: "#23297a"},
{source: "74: competitors apos", target: "74: competitors", fill: "#23297a"},
{source: "74: competitors", target: "74: announcements", fill: "#23297a"},
{source: "74: announcements", target: "74: new products services", fill: "#23297a"},
{source: "74: new products services", target: "74: technological innovations", fill: "#23297a"},
{source: "74: technological innovations", target: "74: Edwards Lifesciences ", fill: "#23297a"},
{source: "74: Edwards Lifesciences ", target: "74: increased expenses whether", fill: "#23297a"},
{source: "74: increased expenses whether", target: "74: marketing raw", fill: "#23297a"},
{source: "74: marketing raw", target: "74: supplies product development", fill: "#23297a"},
{source: "74: supplies product development", target: "74: administration", fill: "#23297a"},
{source: "74: administration", target: "74: economic activity", fill: "#23297a"},
{source: "74: economic activity", target: "74: major regions", fill: "#23297a"},
{source: "74: major regions", target: "74: Edwards Lifesciences ", fill: "#23297a"},
{source: "74: Edwards Lifesciences ", target: "74: possible acquisitions", fill: "#23297a"},
{source: "74: possible acquisitions", target: "74: technologies", fill: "#23297a"},
{source: "74: technologies", target: "74: businesses", fill: "#23297a"},
{source: "74: businesses", target: "74: operations", fill: "#23297a"},
{source: "74: operations", target: "74: expenditures", fill: "#23297a"},
{source: "74: could affect quarterly", target: "81: Edwards Lifesciences ", fill: "#6495ed"},
{source: "81: Edwards Lifesciences ", target: "81: patents could", fill: "#6495ed"},
{source: "81: Edwards Lifesciences ", target: "82: Edwards Lifesciences ", fill: "#324ab2"},
{source: "82: Edwards Lifesciences ", target: "82: also relies on confidentiality agreements with", fill: "#324ab2"},
{source: "82: also relies on confidentiality agreements with", target: "82: certain employees consultants", fill: "#324ab2"},
{source: "82: certain employees consultants", target: "82: proprietary", fill: "#324ab2"},
{source: "82: Edwards Lifesciences ", target: "100: Edwards Lifesciences", fill: "#8f00ff"},
{source: "100: Edwards Lifesciences", target: "100: competes with", fill: "#8f00ff"},
{source: "100: competes with", target: "100: histories better", fill: "#8f00ff"},
{source: "100: histories better", target: "100: name recognition", fill: "#8f00ff"},
{source: "100: name recognition", target: "100: greater access", fill: "#8f00ff"},
{source: "100: greater access", target: "100: resources than", fill: "#8f00ff"},
{source: "100: Edwards Lifesciences", target: "101: Furthermore ", fill: "#fe2712"},
{source: "101: Furthermore ", target: "101: characterized", fill: "#fe2712"},
{source: "101: characterized", target: "101: development", fill: "#fe2712"},
{source: "101: development", target: "101: technology", fill: "#fe2712"},
{source: "101: Furthermore ", target: "105: been consolidating", fill: "#00755e"},
{source: "105: been consolidating", target: "105: transactions with customers", fill: "#00755e"},
{source: "105: transactions with customers", target: "105: longterm contracts", fill: "#00755e"},
{source: "105: been consolidating", target: "108: pricing arrangements with medical supply", fill: "#e97451"},
{source: "108: pricing arrangements with medical supply", target: "108: manufacturers", fill: "#e97451"},
{source: "108: manufacturers", target: "108: distributors", fill: "#e97451"},
{source: "108: distributors", target: "108: negotiated prices", fill: "#e97451"},
{source: "108: pricing arrangements with medical supply", target: "111: Edwards Lifesciences ", fill: "#cd9575"},
{source: "111: Edwards Lifesciences ", target: "111: governmental", fill: "#cd9575"},
{source: "111: governmental", target: "111: regulations", fill: "#cd9575"},
{source: "111: regulations", target: "111: and Edwards Lifesciences ", fill: "#cd9575"},
{source: "111: and Edwards Lifesciences ", target: "111: may incur significant expenses", fill: "#cd9575"},
{source: "111: may incur significant expenses", target: "111: comply with", fill: "#cd9575"},
{source: "111: comply with", target: "111: compatible with", fill: "#cd9575"},
{source: "111: Edwards Lifesciences ", target: "112: manufactured", fill: "#86608e"},
{source: "112: manufactured", target: "112: rigorous regulation by", fill: "#86608e"},
{source: "112: rigorous regulation by", target: "112: United States Food ", fill: "#86608e"},
{source: "112: United States Food ", target: "112: Drug Administration ", fill: "#86608e"},
{source: "112: Drug Administration ", target: "112: governmental authorities", fill: "#86608e"},
{source: "112: manufactured", target: "116: If the FDA ", fill: "#f88379"},
{source: "116: If the FDA ", target: "116: governmental", fill: "#f88379"},
{source: "116: governmental", target: "116: Edwards Lifesciences ", fill: "#f88379"},
{source: "116: Edwards Lifesciences ", target: "116: compliance with applicable", fill: "#f88379"},
{source: "116: compliance with applicable", target: "116: regulations", fill: "#f88379"},
{source: "116: regulations", target: "116: proceedings", fill: "#f88379"},
{source: "116: proceedings", target: "116: products issue", fill: "#f88379"},
{source: "116: products issue", target: "116: recall impose", fill: "#f88379"},
{source: "116: recall impose", target: "116: restrictions", fill: "#f88379"},
{source: "116: restrictions", target: "116: assess civil penalties against", fill: "#f88379"},
{source: "116: assess civil penalties against", target: "116: could recommend criminal prosecution", fill: "#f88379"},
{source: "116: could recommend criminal prosecution", target: "116: Department of Justice", fill: "#f88379"},
{source: "116: If the FDA ", target: "122: actions could", fill: "#fbaed2"},
{source: "122: actions could", target: "122: significant monetary expenditures by", fill: "#fbaed2"},
{source: "122: significant monetary expenditures by", target: "122: Edwards Lifesciences", fill: "#fbaed2"},
{source: "122: Edwards Lifesciences", target: "122: commitment", fill: "#fbaed2"},
{source: "122: commitment", target: "122: management", fill: "#fbaed2"},
{source: "122: management", target: "122: adverse impact on", fill: "#fbaed2"},
{source: "122: adverse impact on", target: "122: financial condition", fill: "#fbaed2"},
{source: "122: financial condition", target: "122: operations", fill: "#fbaed2"},
{source: "122: actions could", target: "128: Company ", fill: "#002395"},
{source: "128: Company ", target: "128: supported by actual longterm studies", fill: "#002395"},
{source: "128: supported by actual longterm studies", target: "128: adversely affected", fill: "#002395"},
{source: "128: Company ", target: "131: Concerns ", fill: "#3c341f"},
{source: "131: Concerns ", target: "131: potential transmission", fill: "#3c341f"},
{source: "131: potential transmission", target: "131: bovine spongiform encephalopathy", fill: "#3c341f"},
{source: "131: bovine spongiform encephalopathy", target: "131: commonly known as", fill: "#3c341f"},
{source: "131: commonly known as", target: "131: quote mad cow disease quote", fill: "#3c341f"},
{source: "131: quote mad cow disease quote", target: "131: humans may", fill: "#3c341f"},
{source: "131: humans may", target: "131: reduced acceptance", fill: "#3c341f"},
{source: "131: reduced acceptance", target: "131: bovine products", fill: "#3c341f"},
{source: "131: Concerns ", target: "134: bovine tissue used", fill: "#f7f"},
{source: "134: bovine tissue used", target: "134: Edwards Lifesciences ", fill: "#f7f"},
{source: "134: Edwards Lifesciences ", target: "134: pericardial tissue", fill: "#f7f"},
{source: "134: pericardial tissue", target: "134: from tissue types", fill: "#f7f"},
{source: "134: from tissue types", target: "134: by global health", fill: "#f7f"},
{source: "134: by global health", target: "134: regulatory", fill: "#f7f"},
{source: "134: regulatory", target: "134: organizations", fill: "#f7f"},
{source: "134: organizations", target: "134: shown no risk", fill: "#f7f"},
{source: "134: shown no risk", target: "134: infectibility", fill: "#f7f"},
{source: "134: infectibility", target: "134: infectious agent", fill: "#f7f"},
{source: "134: bovine tissue used", target: "137: technologies", fill: "#3c1414"},
{source: "137: technologies", target: "137: hospitals doctors", fill: "#3c1414"},
{source: "137: hospitals doctors", target: "137: health care providers", fill: "#3c1414"},
{source: "137: health care providers", target: "137: reimbursement", fill: "#3c1414"},
{source: "137: reimbursement", target: "137: health care services provided", fill: "#3c1414"},
{source: "137: health care services provided", target: "137: patients from", fill: "#3c1414"},
{source: "137: patients from", target: "137: as government programs both domestic", fill: "#3c1414"},
{source: "137: as government programs both domestic", target: "137: international private insurance", fill: "#3c1414"},
{source: "137: international private insurance", target: "137: managed care programs", fill: "#3c1414"},
{source: "137: technologies", target: "144: reimbursement", fill: "#120a8f"},
{source: "144: reimbursement", target: "144: future legislation regulation", fill: "#120a8f"},
{source: "144: future legislation regulation", target: "144: reimbursement policies", fill: "#120a8f"},
{source: "144: reimbursement policies", target: "144: party payors will", fill: "#120a8f"},
{source: "144: party payors will", target: "144: otherwise adversely affect", fill: "#120a8f"},
{source: "144: otherwise adversely affect", target: "144: Edwards Lifesciences ", fill: "#120a8f"},
{source: "144: reimbursement", target: "162: Edwards Lifesciences ", fill: "#ff91a4"},
{source: "162: Edwards Lifesciences ", target: "162: stockholder rights", fill: "#ff91a4"},
{source: "162: stockholder rights", target: "162: bylaws as well", fill: "#ff91a4"},
{source: "162: bylaws as well", target: "162: as provisions", fill: "#ff91a4"},
{source: "162: as provisions", target: "162: Delaware ", fill: "#ff91a4"},
{source: "162: Delaware ", target: "162: agreements", fill: "#ff91a4"},
{source: "162: agreements", target: "162: party could", fill: "#ff91a4"},
{source: "162: party could", target: "162: difficult", fill: "#ff91a4"},
{source: "162: difficult", target: "162: third party", fill: "#ff91a4"},
{source: "162: Edwards Lifesciences ", target: "171: addition certain", fill: "#e5e4e2"},
{source: "171: addition certain", target: "171: control events", fill: "#e5e4e2"},
{source: "171: control events", target: "171: constitute", fill: "#e5e4e2"},
{source: "171: constitute", target: "171: default under", fill: "#e5e4e2"},
{source: "171: default under", target: "171: debt instruments", fill: "#e5e4e2"},
{source: "171: debt instruments", target: "171: instruments", fill: "#e5e4e2"},
{source: "171: instruments", target: "171: receivables", fill: "#e5e4e2"},
{source: "171: receivables", target: "171: facilities", fill: "#e5e4e2"},
{source: "171: facilities", target: "171: borrowings", fill: "#e5e4e2"},
{source: "171: borrowings", target: "171: amounts due under", fill: "#e5e4e2"},
{source: "171: amounts due under", target: "171: receivables facilities becoming immediately due", fill: "#e5e4e2"},
{source: "171: addition certain", target: "172: These ", fill: "#bcd4e6"},
{source: "172: These ", target: "172: Edwards Lifesciences", fill: "#bcd4e6"},
{source: "172: Edwards Lifesciences", target: "172: debt instruments", fill: "#bcd4e6"},
{source: "172: debt instruments", target: "172: receivables facilities", fill: "#bcd4e6"},
{source: "172: receivables facilities", target: "172: employee equity programs", fill: "#bcd4e6"},
{source: "172: employee equity programs", target: "172: control severance", fill: "#bcd4e6"},
{source: "172: control severance", target: "172: agreements with", fill: "#bcd4e6"},
{source: "172: agreements with", target: "172: executive officers which", fill: "#bcd4e6"},
{source: "172: executive officers which", target: "172: accelerating vesting", fill: "#bcd4e6"},
{source: "172: accelerating vesting", target: "172: equity awards", fill: "#bcd4e6"},
{source: "172: equity awards", target: "172: severance payments", fill: "#bcd4e6"},
{source: "172: severance payments", target: "172: payable may also discourage", fill: "#bcd4e6"},
{source: "172: These ", target: "173: Edwards Lifesciences ", fill: "#9bddff"},
{source: "173: Edwards Lifesciences ", target: "173: preferred stock could adversely affect", fill: "#9bddff"},
{source: "173: preferred stock could adversely affect", target: "173: common stock", fill: "#9bddff"},
{source: "173: Edwards Lifesciences ", target: "182: addition increased investor interest", fill: "#d70a53"},
{source: "182: addition increased investor interest", target: "182: rules prohibiting", fill: "#d70a53"},
{source: "182: rules prohibiting", target: "182: organizations from voting", fill: "#d70a53"},
{source: "182: organizations from voting", target: "182: beneficial owner", fill: "#d70a53"},
{source: "182: beneficial owner", target: "182: voting instructions could", fill: "#d70a53"},
{source: "182: voting instructions could", target: "182: difficult", fill: "#d70a53"},
{source: "182: addition increased investor interest", target: "183: difficult", fill: "#73c2fb"},
{source: "183: difficult", target: "183: Edwards Lifesciences ", fill: "#73c2fb"},
{source: "183: Edwards Lifesciences ", target: "183: may incur increased", fill: "#73c2fb"},
{source: "183: may incur increased", target: "183: compensation costs", fill: "#73c2fb"},
{source: "183: compensation costs", target: "183: equity compensation strategy", fill: "#73c2fb"},
{source: "183: equity compensation strategy", target: "183: motivate employees each", fill: "#73c2fb"},
{source: "183: motivate employees each", target: "183: which could", fill: "#73c2fb"},
{source: "183: which could", target: "183: materially adversely affect", fill: "#73c2fb"},
{source: "183: difficult", target: "START_HERE", fill: "#73c2fb"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Global_Industry_Classification_Standard">Global Industry Classification Standard</a></td>
      <td>The Global Industry Classification Standard (GICS) is an industry taxonomy developed in 1999 by MSCI and Standard &amp; Poor's (S&amp;P) for use by the global financial community. The GICS structure consists of 11 sectors, 24 industry groups, 69 industries and 158 sub-industries into which S&amp;P has categorized all major public companies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_general_liability_insurance">Commercial general liability insurance</a></td>
      <td>Commercial general liability insurance is a broad type of insurance policy which provides liability insurance for general business risks.\nCommercial General Liability (CGL) is the specific name for a policy of this type in the United States insurance market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stand-up_meeting">Stand-up meeting</a></td>
      <td>A stand-up meeting is a meeting in which attendees typically participate while standing. The discomfort of standing for long periods is intended to keep the meetings short.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Turbine_engine_failure">Turbine engine failure</a></td>
      <td>A turbine engine failure occurs when a turbine engine unexpectedly stops producing power due to a malfunction other than fuel exhaustion. It often applies for aircraft, but other turbine engines can fail, like ground-based turbines used in power plants or combined diesel and gas vessels and vehicles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet_recession">Balance sheet recession</a></td>
      <td>A balance sheet recession is a type of economic recession that occurs when high levels of private sector debt cause individuals or companies to collectively focus on saving by paying down debt rather than spending or investing, causing economic growth to slow or decline. The term is attributed to economist Richard Koo and is related to the debt deflation concept described by economist Irving Fisher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_Balance_Sheet">Food Balance Sheet</a></td>
      <td>Food balance sheet shows a brief picture of the pattern of the food supply of a country. For each food item, it sketches the primary commodity availability for human consumption i.e.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_alliance">Business alliance</a></td>
      <td>A business alliance is an agreement between businesses, usually motivated by cost reduction and improved service for the customer. Alliances are often bounded by a single agreement with equitable risk and opportunity share for all parties involved and are typically managed by an integrated project team.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales_management">Sales management</a></td>
      <td>Sales management is a business discipline which is focused on the practical application of sales techniques and the management of a firm's sales operations.  It is an important business function as net sales through the sale of products and services and resulting profit drive most commercial business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Marvel_Comics">Marvel Comics</a></td>
      <td>Marvel Comics is the brand name and primary imprint of Marvel Worldwide Inc., formerly Marvel Publishing, Inc. and Marvel Comics Group, a publisher of American comic books and related media.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emotional_labor">Emotional labor</a></td>
      <td>Emotional labor is the process of managing feelings and expressions to fulfill the emotional requirements of a job. More specifically, workers are expected to regulate their emotions during interactions with customers, co-workers and managers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/D*">D*</a></td>
      <td>The Communauté d'agglomération d'Épinal is an administrative association of communes in the Vosges department of eastern France. It was created on 1 January 2013 by the merger of the former Communauté d'agglomération d'Épinal-Golbey, Communauté de communes CAPAVENIR, Communauté de communes du Pays d'Olima et du Val d'Avière, Communauté de communes Est-Épinal Développement and 11 other communes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anti-aliasing_filter">Anti-aliasing filter</a></td>
      <td>An anti-aliasing filter (AAF) is a filter used before a signal sampler to restrict the bandwidth of a signal to satisfy the Nyquist–Shannon sampling theorem over the band of interest. Since the theorem states that unambiguous reconstruction of the signal from its samples is possible when the power of frequencies above the Nyquist frequency is zero, a brick wall filter is an idealized but impractical AAF. A practical AAF makes a trade off between reduced bandwidth and increased aliasing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dwarfism">Dwarfism</a></td>
      <td>Dwarfism describes a condition wherein an organism is exceptionally small, and mostly occurs in the animal kingdom. In humans, it is sometimes defined as an adult height of less than 147 centimetres (4 ft 10 in), regardless of sex; the average adult height among people with dwarfism is 122 centimetres (4 ft 0 in), although some individuals with dwarfism are slightly taller.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Patent_and_Trademark_Office">United States Patent and Trademark Office</a></td>
      <td>The United States Patent and Trademark Office (USPTO) is an agency in the U.S. Department of Commerce that serves as the national patent office and trademark registration authority for the United States. The USPTO's headquarters are in Alexandria, Virginia, after a 2005 move from the Crystal City area of neighboring Arlington, Virginia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Source_protection">Source protection</a></td>
      <td>Source protection, sometimes also referred to as source confidentiality or in the U.S. as the reporter's privilege, is a right accorded to journalists under the laws of many countries, as well as under international law. It prohibits authorities, including the courts, from compelling a journalist to reveal the identity of an anonymous source for a story.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Open_access">Open access</a></td>
      <td>Open access (OA) is a set of principles and a range of practices through which research outputs are distributed online, free of access charges or other barriers. With open access strictly defined (according to the 2001 definition), or libre open access, barriers to copying or reuse are also reduced or removed by applying an open license for copyright.The main focus of the open access movement is "peer reviewed research literature." Historically, this has centered mainly on print-based academic journals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Defence_Headquarters_(Canada)">National Defence Headquarters (Canada)</a></td>
      <td>National Defence Headquarters (NDHQ) (French: Quartiers généraux de la Défense nationale (QGDN)) was created through the integration of  Canadian Armed Forces Headquarters (CAF HQ) with the civilian Department of National Defence (DND) staff.  NDHQ is not a specific location, but is instead housed throughout a collection of offices in buildings across the National Capital Region, although it is most commonly identified with the Major-General George R Pearkes Building on Colonel By Drive in Ottawa.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dutch_cheese_markets">Dutch cheese markets</a></td>
      <td>Dutch cheese farmers traditionally take their cheeses to the town's market square to sell them. Teams (vemen) of official guild cheese-porters (kaasdragers), identified by differently coloured straw hats associated with their forwarding company, carried the farmers' cheese on barrows that weighed about 160 kilograms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Local_government">Local government</a></td>
      <td>Local government is a generic term for the lowest tiers of public administration within a particular sovereign state. This particular usage of the word government refers specifically to a level of administration that is both geographically-localised and has limited powers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_age_restrictions">List of age restrictions</a></td>
      <td>This article gives an outline of age restrictions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fear_of_commitment">Fear of commitment</a></td>
      <td>In self-help literature, fear of commitment is the avoidance of long-term partnership and/or marriage. In popular culture and in psychology, the concept is often much more pervasive and can affect an individual's school, work, and home life as well.The term "commitmentphobia" was coined in the popular self-help book Men Who Can't Love in 1987.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assets_under_management">Assets under management</a></td>
      <td>In finance, assets under management (AUM), sometimes called funds under management, measures the total market value of all the financial assets which an individual or financial institution—such as a mutual fund, venture capital firm, or depository institution—or a decentralized network protocol controls, typically on behalf of a client.  These funds may be managed for clients/users or for themselves in the case of a financial institution which has mutual funds or holds its own venture capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Variant_of_concern">Variant of concern</a></td>
      <td>The term variant of concern (VOC) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, which causes COVID-19) is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity (e.g., N501Y) in RBD-hACE2 complex (genetic data), while also being linked to rapid spread in human populations (epidemiological data).Before this, an emerging variant may have been labeled a variant of interest, or in some countries a variant under investigation. During or after fuller assessment as a variant of concern the variant is typically assigned to a lineage in the PANGOLIN nomenclature system and to clades in the Nextstrain and GISAID systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Connective_tissue_disease">Connective tissue disease</a></td>
      <td>A connective tissue disease (collagenosis) is any disease that has the connective tissues of the body as a target of pathology.  Connective tissue is any type of biological tissue with an extensive extracellular matrix that supports, binds together, and protects organs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Infectivity">Infectivity</a></td>
      <td>In epidemiology, infectivity is the ability of a pathogen to establish an infection.  More specifically, infectivity is a pathogen's capacity for horizontal transmission — that is, how frequently it spreads among  hosts that are not in a parent–child relationship.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_with_universal_health_care">List of countries with universal health care</a></td>
      <td>Universal health coverage is a broad concept that has been implemented in several ways. The common denominator for all such programs is some form of government action aimed at extending access to health care as widely as possible and setting minimum standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Job_interview">Job interview</a></td>
      <td>A job interview is an interview consisting of a conversation between a job applicant and a representative of an employer which is conducted to assess whether the applicant should be hired. Interviews are one of the most popularly used devices for employee selection.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/By-law">By-law</a></td>
      <td>Law is a system of rules created and enforced through social or governmental institutions to regulate behavior, with its precise definition a matter of longstanding debate. It has been variously described as a science and the art of justice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Percussion_instrument">Percussion instrument</a></td>
      <td>A percussion instrument is a musical instrument that is sounded by being struck or scraped by a beater including attached or enclosed beaters or rattles struck, scraped or rubbed by hand or struck against another similar instrument. Excluding zoomusicological instruments and the human voice, the percussion family is believed to include the oldest musical instruments.The percussion section of an orchestra most commonly contains instruments such as the timpani, snare drum, bass drum, cymbals, triangle and tambourine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bullet_hit_squib">Bullet hit squib</a></td>
      <td>A bullet hit squib or a blood squib is a practical, pyrotechnic special effect device used in the film industry, theatre productions and first responder moulage training to simulate a wound spurting blood from a bullet impact. Even if the portrayal is not necessarily accurate or is exaggerated compared to real-life (in the example of the main figure, blood spews out of a thick coat while emitting smoke), filmmakers and the audience have become accustomed to associating this aesthetic with a gunshot wound.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jim_Corbett_National_Park">Jim Corbett National Park</a></td>
      <td>Jim Corbett National Park is a national park in India located in the Nainital district of  Uttarakhand state.  The first national park in India, it was established in 1936 during the British Raj and named Hailey National Park after William Malcolm Hailey, a governor of the United Provinces in which it was then located.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>EDWARDS LIFESCIENCES CORP        Item 1A   <font color="blue">Risk Factors   </font>10     Item 1A    <font color="blue">Risk Factors   </font>               An investor should carefully consider the <font color="blue">risks described</font> below, as     well as other information contained in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">filings with</font>     the <font color="blue">Securities and Exchange Commission</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">events described</font> below     occurs, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  business, <font color="blue">financial condition</font> or results of     <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>In that case, the value of Edwards     <font color="blue">Lifesciences </font>&amp;apos  <font color="blue">securities could decline</font> and an <font color="blue">investor may lose</font> part or all     of his or her <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>does not <font color="blue">introduce <font color="blue">new products</font></font> in a <font color="blue">timely manner</font>,     its <font color="blue"><font color="blue">products may</font> become obsolete</font> and its operating results may suffer</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">cardiovascular</font> products industry</font> is <font color="blue"><font color="blue">characterized</font> by rapid</font>     <font color="blue">technological</font> changes, <font color="blue">frequent new product <font color="blue">introduction</font>s</font> and evolving     <font color="blue">industry standards</font></td>
    </tr>
    <tr>
      <td>Without the timely <font color="blue">introduction</font> of <font color="blue">new products</font> and     <font color="blue">enhancements</font>,   Edwards  <font color="blue">Lifesciences </font>&amp;apos   products  will  likely  become     <font color="blue">technological</font>ly obsolete over time, in which case its revenue and operating     results <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is able to develop new     <font color="blue">technologies</font>, these <font color="blue">technologies</font> may not be <font color="blue">accepted quickly</font> because of     industry  specific factors, such as the need for <font color="blue"><font color="blue">regulatory</font> clearance</font>,     unanticipated <font color="blue">restrictions</font> imposed on approved indications, entrenched     patterns  of  clinical  practice  and  <font color="blue">uncertainty</font>  over  third  party     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue"><font color="blue">significant</font> technical <font color="blue">innovations</font> <font color="blue">generally</font> will</font> require a     substantial  <font color="blue">investment</font>  before <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>can determine the     <font color="blue">commercial viability</font> of these <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may not have     the <font color="blue">financial resources necessary</font> to fund these technical <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td>In     addition, even if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is able to <font color="blue">successfully</font> develop     <font color="blue">enhancements</font> or new <font color="blue">generations</font> of its products, these <font color="blue">enhancements</font> or new     <font color="blue">generations</font> of <font color="blue">products may</font> not produce revenue in excess of the costs of     <font color="blue">development</font>, and they may be quickly rendered <font color="blue">obsolete by</font> changing customer     <font color="blue">preferences</font> or the <font color="blue"><font color="blue">introduction</font> by</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">competitors</font> of     products embodying new <font color="blue">technologies</font> or features</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">may incur product <font color="blue">liability</font> losses</font> that <font color="blue">could <font color="blue">adversely</font></font>     affect its operating results</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  business exposes it to <font color="blue">potential product</font>     <font color="blue"><font color="blue">liability</font> risks</font> that are inherent in the design, <font color="blue">manufacture</font> and marketing     of  medical  devices</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  products are often used in     surgical  and  <font color="blue">intensive care settings with seriously ill patients</font></td>
    </tr>
    <tr>
      <td>In     addition, some of the <font color="blue">medical devices <font color="blue">manufacture</font>d</font> and sold by Edwards     <font color="blue">Lifesciences </font>are designed to be implanted in the human body for <font color="blue">long periods</font>     of time</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>could be the subject of product <font color="blue">liability</font>     suits alleging that component failures, manufacturing flaws, design defects     or  inadequate  <font color="blue">disclosure</font> of product related risks or product related     information could result in an <font color="blue">unsafe condition</font> or injury to patients</td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">liability</font> lawsuits</font> and claims, <font color="blue">safety alerts</font> or <font color="blue">product recalls</font> in     the future, regardless of their ultimate outcome, could have a material     adverse effect on <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  business and reputation and on its     ability to attract and retain customers</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________       <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may experience <font color="blue">supply interruptions</font> that <font color="blue">could harm</font> its     ability to <font color="blue"><font color="blue">manufacture</font> products</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>uses a diverse and <font color="blue">broad range</font> of raw and     <font color="blue">organic materials</font> and other items in the design and <font color="blue">manufacture</font> of its     products</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font>&amp;apos   heart  valve  therapy  products are     <font color="blue">manufacture</font>d from treated natural animal tissue and man-made materials</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font>&amp;apos   non-implantable products are <font color="blue">manufacture</font>d from     man-made <font color="blue">raw materials</font> including resins, chemicals, electronics and metals</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">purchases certain</font> of the materials and <font color="blue"><font color="blue">components</font> used</font>     in the <font color="blue">manufacture</font> of its <font color="blue">products from external suppliers</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">purchases certain</font> supplies from single sources for     reasons of quality assurance, cost-<font color="blue">effectiveness</font> or <font color="blue">constraints</font> resulting     <font color="blue">from <font color="blue">regulatory</font> <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>works <font color="blue">closely with</font> its     suppliers to <font color="blue">assure continuity</font> of <font color="blue">supply while</font> maintaining <font color="blue">high quality</font> and     <font color="blue">re<font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Alternative </font><font color="blue">supplier options</font> are <font color="blue">generally</font> considered and     identified,  although  Edwards  <font color="blue">Lifesciences </font>does not <font color="blue">typically pursue</font>     <font color="blue"><font color="blue">regulatory</font> qualification</font> of <font color="blue">alternative sources due</font> to the strength of its     <font color="blue">existing supplier relationships</font> and the time and <font color="blue">expense associated with</font>     this  <font color="blue"><font color="blue">regulatory</font> process</font></td>
    </tr>
    <tr>
      <td>Although a change in suppliers could require     <font color="blue">significant</font> effort or <font color="blue">investment</font> by <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>in <font color="blue">circumstances</font>     where the items supplied are integral to the performance of its products or     incorporate unique <font color="blue">technology</font>, <font color="blue">management</font> does not believe that the loss of     any <font color="blue">existing supply contract would</font> have a material adverse effect on the     Company</td>
    </tr>
    <tr>
      <td>In an effort to reduce <font color="blue">potential product</font> <font color="blue">liability</font> exposure, in the     <font color="blue">past certain suppliers</font> have announced that they <font color="blue">might limit</font> or terminate     sales  of  certain  materials  and parts to companies that <font color="blue">manufacture</font>     <font color="blue">implantable medical devices</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is unable to obtain     these <font color="blue">raw materials</font> or there is a <font color="blue">significant</font> increase in the price of     materials or <font color="blue">components</font>, its business could be harmed</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be required to recognize <font color="blue">additional charges</font> in     <font color="blue">connection with</font> the write-down of some of its <font color="blue">investment</font>s, the <font color="blue">disposition</font>     of  some  of its <font color="blue">businesses</font>, the <font color="blue">termination</font> of its <font color="blue">interest rate swap</font>     <font color="blue">agreements</font> or for other reasons</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has made <font color="blue">investment</font>s in the <font color="blue">equity <font color="blue">instruments</font></font>     of other companies, and may make further such <font color="blue">investment</font>s in the future</td>
    </tr>
    <tr>
      <td>To     the  extent  that  the  value of any such <font color="blue">investment</font> declines, Edwards     <font color="blue">Lifesciences </font>may be required to recognize charges to write down the value of     that <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>See  &amp;quote <font color="blue">Asset Impairments </font>&amp;quote  under  &amp;quote Managementapstas Discussion and     Analysis of Financial Condition and Results of Operations &amp;quote  included herein</td>
    </tr>
    <tr>
      <td>In the case of some of the companies in which <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>    has invested, the value of its <font color="blue">equity securities</font> has <font color="blue">declined since</font> the time     of  its  original <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>As a result, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be     required to recognize <font color="blue">additional charges</font>, <font color="blue">which could</font> be substantial, to     write down its <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>had     dlra10dtta7 million of <font color="blue">investment</font>s in <font color="blue">equity <font color="blue">instruments</font></font> of other companies and     had <font color="blue">recorded unrealized losses</font> of dlra0dtta6 million on these <font color="blue">investment</font>s on its     <font color="blue">balance sheet</font> in  &amp;quote Accumulated Other Comprehensive Income (Loss), &amp;quote  net of     tax</td>
    </tr>
    <tr>
      <td>As part of the <font color="blue">ongoing <font color="blue">evaluation</font></font> of its various <font color="blue">businesses</font> and     products, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>from time to time identifies <font color="blue">businesses</font> or     products that are not performing at a <font color="blue">level commensurate with</font> the rest of     its business</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may from time to time seek to dispose of     these under-performing <font color="blue">businesses</font> or <font color="blue">product lines</font>, and <font color="blue">may also seek</font> to     dispose of <font color="blue">businesses</font> or <font color="blue">product lines</font> from time to time for strategic or     other business reasons</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is unable to dispose of a     business  or  product  line  on terms it considers acceptable, Edwards     <font color="blue">Lifesciences </font><font color="blue">may voluntarily terminate</font> that business or <font color="blue">cease providing</font> that     product</td>
    </tr>
    <tr>
      <td>Any  of  these  events may result in charges, <font color="blue">which could</font> be     substantial and which <font color="blue">could <font color="blue">adversely</font></font> affect its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Historically, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has <font color="blue">entered into interest rate</font>     swap <font color="blue">agreements</font> in <font color="blue">connection with</font> some of its <font color="blue">indebtedness</font>, and expects     that it <font color="blue">will continue</font> to do so from time to time in the                                         11       _________________________________________________________________       future</td>
    </tr>
    <tr>
      <td>In the event that <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>elects to terminate a swap     <font color="blue">agreement prior</font> to its maturity, it may be required to make <font color="blue">cash payments</font> to     the  <font color="blue">counterparty</font>  and  to  recognize a charge in <font color="blue">connection with</font> that     <font color="blue">termination</font>, which <font color="blue">could <font color="blue">adversely</font></font> affect its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may not <font color="blue">successfully</font> identify and complete <font color="blue"><font color="blue">acquisition</font>s</font>     or <font color="blue"><font color="blue"><font color="blue">strategic alliance</font>s</font> on</font> favorable terms or achieve anticipated synergies     relating to any <font color="blue"><font color="blue">acquisition</font>s</font> or alliances, and such <font color="blue"><font color="blue">acquisition</font>s</font> could     result  in unforeseen operating <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue">expenditures</font>, require     <font color="blue">significant</font>  <font color="blue">management</font>  resources  and require <font color="blue">significant</font> charges or     write-downs</td>
    </tr>
    <tr>
      <td>As  part  of  Edwards  <font color="blue">Lifesciences </font>&amp;apos   <font color="blue">growth strategy</font>, Edwards     <font color="blue">Lifesciences </font>regularly reviews potential <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">complementary</font>     <font color="blue">businesses</font>,  <font color="blue">technologies</font>,  services or products, as well as potential     <font color="blue"><font color="blue">strategic alliance</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be unable to <font color="blue">find suitable</font>     <font color="blue">acquisition</font>  <font color="blue">candidates</font>  or  <font color="blue">appropriate</font>  partners  with which to form     <font color="blue">partnerships</font> or <font color="blue"><font color="blue">strategic alliance</font>s</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>identifies     <font color="blue">appropriate</font> <font color="blue">acquisition</font> or alliance <font color="blue">candidates</font>, it may be unable to complete     such <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">alliances on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>In addition,     the process of integrating an acquired business, <font color="blue">technology</font>, service or     <font color="blue">product into</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  existing business and <font color="blue">operations</font> may     result in unforeseen operating <font color="blue"><font color="blue">difficult</font>ies</font> and <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integration </font>of     an acquired company also may require <font color="blue">significant</font> <font color="blue">management</font> resources that     otherwise  would  be  available  for  ongoing  <font color="blue">development</font>  of Edwards     <font color="blue">Lifesciences </font>&amp;apos  business</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may not realize the     anticipated benefits of any <font color="blue">acquisition</font> or <font color="blue">strategic alliance</font>, and such     <font color="blue"><font color="blue">transaction</font>s may</font> not generate anticipated financial results</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be required to take charges or <font color="blue">write downs</font> in     <font color="blue">connection with</font> <font color="blue"><font color="blue">acquisition</font>s</font> it has made or may make in the future</td>
    </tr>
    <tr>
      <td>In     particular, <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">businesses</font> engaged in the <font color="blue">development</font> of new     <font color="blue">products may</font> give rise to in-process research and <font color="blue">development</font> charges, which     could be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has taken in-process research and     <font color="blue">development</font>  charges in <font color="blue">connection with</font> past <font color="blue"><font color="blue">acquisition</font>s</font> and may take     similar charges in <font color="blue">connection with</font> <font color="blue"><font color="blue">acquisition</font>s</font> the Company makes in the     future, which charges <font color="blue">could <font color="blue">adversely</font></font> affect its results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">acquisition</font>s</font> could also require issuances of <font color="blue">equity securities</font>, the     incurrence of debt, contingent <font color="blue">liabilities</font> or <font color="blue">amortization expenses</font> related     to other <font color="blue">intangible assets</font>, any of which <font color="blue">could harm</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos      business</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  business is subject to economic, political and other     <font color="blue"><font color="blue">risks associated with</font> international sales</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>sells its products in a number of     <font color="blue">foreign countries</font>, its business is subject to <font color="blue">risks associated with</font> doing     business  <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">net sales originating</font>     outside of the <font color="blue">United States</font>, as a percentage of <font color="blue">total net sales</font>, were 54dtta3prca     in 2005</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>anticipates that sales from international     <font color="blue">operations</font> <font color="blue">will continue</font> to represent a substantial portion of its total     sales</td>
    </tr>
    <tr>
      <td>In addition, many of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">manufacturing <font color="blue">facilities</font></font>     and suppliers are <font color="blue">located outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>expects     to increase <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  international sales, <font color="blue">which could</font> expose it     to  greater  <font color="blue"><font color="blue">risks associated with</font> international sales</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Accordingly,  <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>future results could be <font color="blue">harmed by</font> a     variety of factors, including:          •                 changes in foreign medical <font color="blue">reimbursement</font> policies and programs;          •                 unexpected changes in <font color="blue">foreign <font color="blue">regulatory</font> <font color="blue">requirements</font></font>;          •                 changes in <font color="blue">foreign currency exchange rates</font>;          •                 changes  in  a specific countryapstas or regionapstas political or                 economic <font color="blue">conditions</font>, particularly in <font color="blue">emerging regions</font>;          •                 trade  protection  measures and import or <font color="blue">export licensing</font>                 <font color="blue">requirements</font>;          •                 <font color="blue">potentially negative consequences from</font> changes in tax laws;                                         12       _________________________________________________________________       •            <font color="blue"><font color="blue">difficult</font>y</font> in staffing and managing foreign <font color="blue">operations</font>;     •            an outbreak of any <font color="blue">life threatening communicable disease</font>;     •            changes in the <font color="blue">international political</font> situation;     •            <font color="blue">differing labor <font color="blue">regulations</font></font>; and     •            <font color="blue">differing protection</font> of <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is subject to risks arising <font color="blue">from currency exchange rate</font>     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>generated 54dtta3prca of net sales in 2005 outside of     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">sales outside</font>     of the <font color="blue"><font color="blue">United States</font> </font>are <font color="blue">denominated</font> in <font color="blue">local currencies</font></td>
    </tr>
    <tr>
      <td>Measured in local     currency, a substantial portion of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">foreign generated</font>     sales was generated in Europe (and primarily <font color="blue">denominated</font> in the Euro) and in     Japan</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States</font> </font><font color="blue">dollar value</font> of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  foreign     generated sales varies with currency exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Significant </font>    </font><font color="blue">decreases</font>  in the value of the <font color="blue"><font color="blue">United States</font> </font>dollar to the Euro or the     <font color="blue">Japanese  </font>yen  have had the effect of increasing <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos      earnings  even when the volume of <font color="blue">foreign sales</font> has <font color="blue">remained constant</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>increases in the value of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">dollar relative</font> to     the <font color="blue">Euro or the Japanese </font>yen, as well as other currencies, could have a     material adverse effect on <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has a hedging program that attempts to <font color="blue">manage currency</font>     <font color="blue">exchange rate risks</font> to an acceptable level based on <font color="blue">management</font>apstas judgment of     the <font color="blue">appropriate</font> trade-off between risk, opportunity and cost; however, this     hedging  program does not <font color="blue">completely eliminate</font> the effects of currency     exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font><font color="blue"><font color="blue">interest rates</font> <font color="blue">could increase</font></font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  borrowing     costs and make it more <font color="blue">difficult</font> to access the <font color="blue">capital markets</font></td>
    </tr>
    <tr>
      <td>From time to time <font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">may issue securities</font> to     finance  <font color="blue"><font color="blue">acquisition</font>s</font>, capital <font color="blue">expenditures</font>, working capital and other     <font color="blue">general corporate purposes</font></td>
    </tr>
    <tr>
      <td>An increase in <font color="blue">interest rates</font> in the general     <font color="blue">economy could</font> result in an increase in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">borrowing costs</font>     for these financings, as well as under any <font color="blue">existing debt</font> that <font color="blue">bears interest</font>     at a <font color="blue">floating rate</font> and for which <font color="blue">interest rate swap</font>s are not in place, and     <font color="blue">could otherwise restrict</font> the ability of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>to access the     <font color="blue">capital markets</font></td>
    </tr>
    <tr>
      <td>Fluctuations in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  quarterly operating results may cause     its stock price to decline</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font>&amp;apos   sales  and  operating results may vary     <font color="blue">significant</font>ly  from  quarter  to quarter</td>
    </tr>
    <tr>
      <td>A <font color="blue">high proportion</font> of Edwards     <font color="blue">Lifesciences </font>&amp;apos  costs are fixed, due in part to <font color="blue">significant</font> sales, research     and <font color="blue">development</font> and <font color="blue">manufacturing costs</font></td>
    </tr>
    <tr>
      <td>Thus, small declines in revenue     <font color="blue">could disproportionately affect</font> operating results in a quarter, and the     price of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue"><font color="blue"><font color="blue">common stock</font> may</font> fall</font></td>
    </tr>
    <tr>
      <td>Other factors that     <font color="blue">could affect quarterly</font> operating results include:          •                 demand for and <font color="blue">clinical acceptance</font> of products;          •                 the timing and execution of customer contracts, particularly                 large  contracts  that  would  <font color="blue">materially</font>  affect  Edwards                 <font color="blue">Lifesciences </font>&amp;apos  operating results in a <font color="blue">given quarter</font>;          •                 the timing of sales of products and of the <font color="blue">introduction</font> of new                 products;          •                 changes in <font color="blue">foreign currency exchange rates</font>;                                         13       _________________________________________________________________            •                 <font color="blue">unanticipated delays</font> or problems in <font color="blue">introducing <font color="blue">new products</font></font>;          •                 <font color="blue">competitors</font> &amp;apos   <font color="blue">announcements</font>  of  <font color="blue">new products</font>, services or                 <font color="blue">technological</font> <font color="blue">innovations</font>;          •                 changes in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  pricing policies or the pricing                 policies of its <font color="blue">competitors</font>;          •                 increased expenses, whether related to sales and marketing, raw                 materials or supplies, product <font color="blue">development</font> or <font color="blue">administration</font>;          •                 adverse changes in the level of <font color="blue">economic activity</font> in the United                 States and other <font color="blue">major regions</font> in which <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>                does business;          •                 costs  related to possible <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">technologies</font> or                 <font color="blue">businesses</font>;          •                 <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  ability to expand its <font color="blue">operations</font>; and          •                 the amount and timing of <font color="blue">expenditures</font> related to expansion of                 <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">inability</font> to protect its <font color="blue"><font color="blue">intellectual</font> property</font> could     have a material adverse effect on its business</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font>&amp;apos   success  and  <font color="blue">competitive position</font> are     <font color="blue">dependent</font>, in part, upon its <font color="blue">proprietary</font> <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Edwards     <font color="blue">Lifesciences </font> relies  on  a  <font color="blue">combination</font> of patents, trade secrets and     non<font color="blue">disclosure</font> <font color="blue">agreements</font> to protect its <font color="blue">proprietary</font> <font color="blue"><font color="blue">intellectual</font> property</font>,     and <font color="blue">will continue</font> to do so</td>
    </tr>
    <tr>
      <td>Although <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>seeks to protect     its <font color="blue"><font color="blue">proprietary</font> rights through</font> a variety of means, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>    <font color="blue">cannot guarantee</font> that the protective steps it has taken are adequate to     protect these rights</td>
    </tr>
    <tr>
      <td>Patents issued to or <font color="blue">licensed by</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>    in  the  past  or in the <font color="blue">future may</font> be challenged and held invalid</td>
    </tr>
    <tr>
      <td>In     addition, certain of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  patents are due to expire within     the <font color="blue">next five years</font> and the Company may be <font color="blue">unsuccessful</font> in its efforts to     extend its protection through improvement patents, modifications or line     <font color="blue">extensions</font></td>
    </tr>
    <tr>
      <td>The failure to maintain <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">patents could</font> have     a material adverse effect on the Company</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>also relies on confidentiality <font color="blue">agreements</font> with     certain employees, consultants and other parties to protect, in part, trade     secrets  and  other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> could be     breached and <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may not have <font color="blue">adequate remedies</font> for any     breach</td>
    </tr>
    <tr>
      <td>In  addition,  others may in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> information or <font color="blue">gain access</font> to <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos      trade  secrets or <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>spends     <font color="blue">significant</font> resources to monitor and enforce its <font color="blue"><font color="blue">intellectual</font> property</font>     rights</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may not be able to detect <font color="blue">infringement</font> and may lose its     <font color="blue">competitive position</font> in the industry</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">competitors</font> may design     around <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">technology</font> or develop competing <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">litigation</font> could</font> result in substantial cost and diversion of effort</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue"><font color="blue">property rights</font> may also</font> be unavailable or limited in some     <font color="blue">foreign countries</font>, <font color="blue">which could</font> make it easier for <font color="blue">competitors</font> to capture     <font color="blue">increased market position</font></td>
    </tr>
    <tr>
      <td>Third  parties  may  claim  Edwards  <font color="blue">Lifesciences </font> is infringing their     <font color="blue"><font color="blue">intellectual</font> property</font>, and <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>could suffer <font color="blue">significant</font>     <font color="blue">litigation</font> or <font color="blue">licensing expenses</font> or be <font color="blue">prevented from selling products</font></td>
    </tr>
    <tr>
      <td>During <font color="blue">recent years</font>, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">competitors</font> have been     involved in substantial <font color="blue">litigation</font> regarding patent and other <font color="blue">intellectual</font>     <font color="blue">property rights</font> in the medical device industry <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>From time to time,     <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be forced to <font color="blue">defend itself against</font> other claims and     <font color="blue">legal actions</font> alleging <font color="blue">infringement</font> of the <font color="blue"><font color="blue">intellectual</font> property</font> rights of     others</td>
    </tr>
    <tr>
      <td>Because <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> can be costly and time     consuming, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> expenses     could be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>Adverse de<font color="blue">termination</font>s in any such <font color="blue"><font color="blue">litigation</font> could</font>     subject <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>to <font color="blue">significant</font> <font color="blue">liabilities</font> to third parties, or     could require <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>to seek licenses from third parties and     could, if such licenses are not available, prevent the Company from                                         14       _________________________________________________________________       manufacturing, selling or <font color="blue">using certain</font> of its products, any one of which     could have a material adverse effect on the Company</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties could also</font> obtain patents that may require Edwards     <font color="blue">Lifesciences </font>to either redesign its products or, if possible, negotiate     licenses to conduct its business</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is unable to     redesign its products or obtain a license, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may have to     exit a <font color="blue">particular product offering</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">faces intense competition</font> and <font color="blue">consolidation within</font> its     industry, and if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>does not <font color="blue">compete effectively</font>, its     business will be harmed</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">cardiovascular</font> medical</font> device industry is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">competes with</font> many companies, some of which have longer     operating histories, better brand or <font color="blue">name recognition</font> and <font color="blue">greater access</font> to     financial and other <font color="blue">resources than</font> <font color="blue">Edwards Lifesciences</font></td>
    </tr>
    <tr>
      <td>Furthermore, the     industry is <font color="blue">characterized</font> by intensive <font color="blue">development</font> efforts and rapidly     advancing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  present and <font color="blue">future products</font>     could be rendered obsolete or uneconomical by <font color="blue">technological</font> advances made by     one  or  more  of  its current or future <font color="blue">competitors</font> or <font color="blue">by alternative</font>     therapies, including <font color="blue">drug therapies</font></td>
    </tr>
    <tr>
      <td>See  &amp;quote Business—Competition &amp;quote  included     herein</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">future success will depend</font>, in large part, on     its ability to develop and acquire <font color="blue">new products</font> and <font color="blue">technologies</font>, anticipate     <font color="blue">technology</font> advances and keep pace with other <font color="blue">developers</font> of <font color="blue">cardiovascular</font>     therapies and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The medical device industry has <font color="blue">been consolidating</font> and, as a result,     <font color="blue"><font color="blue">transaction</font>s with customers</font> are larger, more complex and tend to involve     more long-term contracts</td>
    </tr>
    <tr>
      <td>The <font color="blue">enhanced purchasing power</font> of these larger     customers  may  <font color="blue">also increase downward pressure on product pricing</font></td>
    </tr>
    <tr>
      <td>In     addition,  many  existing and <font color="blue">potential domestic customers</font> for Edwards     <font color="blue">Lifesciences </font>&amp;apos  products have combined to form group <font color="blue">purchasing <font color="blue">organizations</font></font>,     or   &amp;quote GPOs &amp;quote</td>
    </tr>
    <tr>
      <td>GPOs  negotiate  <font color="blue">pricing arrangements with medical supply</font>     <font color="blue">manufacture</font>rs  and  <font color="blue">distributors</font>  and these <font color="blue">negotiated prices</font> are made     available to members of GPOs</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is not one of the     providers  selected by a GPO, it may be <font color="blue">precluded from</font> making sales to     members  of a GPO Even if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is one of the selected     providers, it may be at a <font color="blue">disadvantage relative</font> to other <font color="blue">selected providers</font>     that are able to <font color="blue">offer volume discounts based on purchases</font> of a broader     range of <font color="blue">medical equipment</font> and supplies</td>
    </tr>
    <tr>
      <td>Further, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may     be required to commit to pricing that has a material adverse effect on its     sales and <font color="blue">profit margins</font>, business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>and its customers are subject to various <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">regulations</font> and <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may incur <font color="blue">significant</font> expenses to     <font color="blue">comply with</font> these <font color="blue">regulations</font> and develop its products to be <font color="blue">compatible with</font>     these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The  medical  devices  <font color="blue">manufacture</font>d  and  marketed  by Edwards     <font color="blue">Lifesciences </font>are subject to <font color="blue">rigorous regulation by</font> the <font color="blue"><font color="blue">United States</font> </font>Food     and  Drug Administration ( &amp;quote FDA &amp;quote ) and numerous other federal, state and     foreign  <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">regulatory</font>     approvals to market a medical device, <font color="blue">particularly from</font> the FDA and certain     foreign <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font>, can be costly and time consuming, and     approvals might not be granted for <font color="blue">future products</font> on a timely basis, if at     all</td>
    </tr>
    <tr>
      <td>Delays in receipt of, or failure to obtain, approvals for future     <font color="blue">products could</font> result in <font color="blue">delayed realization</font> of <font color="blue">product revenues</font> or in     substantial additional costs, <font color="blue">which could</font> have material <font color="blue">adverse effects on</font>     <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  business or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, there     can be no assurance that <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>will be or <font color="blue">will continue</font> to be     in  compliance  with  applicable  FDA  and  other  material <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or some other foreign <font color="blue"><font color="blue">government</font>al</font> authority were     to conclude that <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>was not in <font color="blue">compliance with applicable</font>     laws or <font color="blue">regulations</font>, the FDA or such other foreign <font color="blue"><font color="blue">government</font>al</font> authority,     as  applicable, could institute <font color="blue">proceedings</font> to detain or seize Edwards     <font color="blue">Lifesciences </font>&amp;apos  products, issue a recall, impose operating <font color="blue">restrictions</font>,     enjoin  future  violations  and <font color="blue">assess civil penalties against</font> Edwards     Lifesciences, its officers or its employees                                         15       _________________________________________________________________       and <font color="blue">could recommend criminal prosecution</font> to the <font color="blue">Department of Justice</font></td>
    </tr>
    <tr>
      <td>Moreover, the FDA or some other foreign <font color="blue"><font color="blue">government</font>al</font> authority could proceed     to ban, or request recall, repair, <font color="blue">replacement</font> or refund of the cost of, any     device or product <font color="blue">manufacture</font>d or <font color="blue">distributed by</font> <font color="blue">Edwards Lifesciences</font></td>
    </tr>
    <tr>
      <td>Furthermore, both the FDA and foreign <font color="blue">government</font> <font color="blue">regulators</font> have become     increasingly stringent, and <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>may be subject to more     <font color="blue">rigorous regulation by</font> <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> in the future</td>
    </tr>
    <tr>
      <td>Failure of any of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  products to <font color="blue">meet applicable quality</font>     <font color="blue">standards could</font> result in recalls or other <font color="blue">serious consequences</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">products must conform with exacting quality</font>     standards, many of which are imposed by <font color="blue">regulations</font> of the FDA and other     applicable <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue"><font color="blue">manufacture</font> products</font> to the     required quality <font color="blue">standards could</font> result in voluntary or <font color="blue">mandatory recalls</font> of     the products, field corrective actions or other remedial action, as well as     fines and penalties or the ban of the <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">actions could</font>     result in <font color="blue">significant</font> monetary <font color="blue">expenditures</font> by <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>as well     as the <font color="blue">commitment</font> of substantial amounts of <font color="blue">management</font> time and could have a     material <font color="blue">adverse impact on</font> the <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     of <font color="blue">Edwards Lifesciences</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unsuccessful  </font>clinical  trials or <font color="blue">development</font>al procedures relating to     products and <font color="blue">development</font> could have a material adverse effect on Edwards     <font color="blue">Lifesciences </font>&amp;apos  prospects</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue">new products</font> by <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>requires     extensive <font color="blue">clinical trials</font> and procedures</td>
    </tr>
    <tr>
      <td>There can be no assurance that     these trials or <font color="blue">procedures will</font> be successful or completed in a timely or     <font color="blue">cost effective manner</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">successfully</font> complete these trials or     procedures in a timely and <font color="blue">cost effective manner</font> could have a material     adverse effect on the Companyapstas prospects</td>
    </tr>
    <tr>
      <td>In addition, current results from     the Companyapstas <font color="blue">clinical trials</font> or <font color="blue">procedures may</font> not be <font color="blue">supported by actual</font>     long-term studies or clinical experience</td>
    </tr>
    <tr>
      <td>If current results for a <font color="blue">Company     </font>product  cannot  be  <font color="blue">supported by actual</font> long-term studies or clinical     experience, the Companyapstas business could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font>is subject to risks arising from concerns and/or     <font color="blue">regulatory</font> actions relating to  &amp;quote mad cow disease &amp;quote</td>
    </tr>
    <tr>
      <td>Certain of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  products, including pericardial     <font color="blue">tissue valves</font>, are <font color="blue">manufacture</font>d using bovine tissue</td>
    </tr>
    <tr>
      <td><font color="blue">Concerns </font>relating to     the <font color="blue">potential transmission</font> of <font color="blue">bovine spongiform encephalopathy</font>, or  &amp;quote BSE, &amp;quote      <font color="blue">commonly known as</font>  &amp;quote mad cow disease, &amp;quote  from cows to <font color="blue">humans may</font> result in     <font color="blue">reduced acceptance</font> of <font color="blue">bovine products</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>obtains its     bovine tissue only from closely controlled sources within the <font color="blue"><font color="blue">United States</font> </font>    and Australia</td>
    </tr>
    <tr>
      <td>To date, there have been few reported cases in the United     States</td>
    </tr>
    <tr>
      <td>The <font color="blue">bovine tissue used</font> in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">pericardial tissue</font>     valves is <font color="blue">from tissue types</font> considered <font color="blue">by global health</font> and <font color="blue">regulatory</font>     <font color="blue">organizations</font> to have <font color="blue">shown no risk</font> of <font color="blue">infectibility</font> for the suspected BSE     <font color="blue">infectious agent</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has not experienced any <font color="blue">significant</font>     <font color="blue">adverse impact on</font> its sales as a result of concerns regarding BSE, but no     assurance can be given that such an <font color="blue">impact may</font> not occur in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">third <font color="blue">party payors</font> decline</font> to reimburse <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  customers     for its products or reduce <font color="blue">reimbursement</font> levels, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos      ability to <font color="blue">profitably sell</font> its <font color="blue">products will</font> be harmed</td>
    </tr>
    <tr>
      <td>Edwards  <font color="blue">Lifesciences </font> sells  its products and <font color="blue">technologies</font> to     hospitals, doctors and other <font color="blue">health care providers</font>, all of which receive     <font color="blue">reimbursement</font> for the <font color="blue">health care services provided</font> to its <font color="blue">patients from</font>     third  party  payors,  such  as <font color="blue">government</font> programs (both domestic and     international), private insurance plans and <font color="blue">managed care programs</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>third <font color="blue">party payors</font> may deny <font color="blue">reimbursement</font> if they determine that a device     used in a procedure was not used in accordance with cost-effective treatment     methods  as  determined <font color="blue">by such third <font color="blue">party payors</font></font>, or was used for an     <font color="blue">unapproved indication</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payors</font>                                         16       _________________________________________________________________       <font color="blue">may also decline</font> to reimburse for <font color="blue">experimental procedures</font> and devices</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>believes that many of its existing and <font color="blue">future products</font>     are cost-effective because they are intended to <font color="blue">reduce overall health care</font>     <font color="blue">costs over</font> a long period of time</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>cannot be certain     whether these third <font color="blue">party payors</font> will recognize these <font color="blue">cost savings</font> or will     <font color="blue">merely focus on</font> the lower initial costs associated with competing therapies</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  products are not considered cost-effective by third     <font color="blue">party payors</font>, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">customers may</font> not be reimbursed for the     Companyapstas products</td>
    </tr>
    <tr>
      <td>In addition, third <font color="blue">party payors</font> are <font color="blue">increasingly attempting</font> to     contain  health  <font color="blue">care costs by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>There can be no assurance     that levels of <font color="blue">reimbursement</font>, if any, will not be decreased in the future,     or that future legislation, regulation or <font color="blue">reimbursement</font> policies of third     <font color="blue">party payors</font> will not otherwise <font color="blue">adversely</font> affect the demand for and price     levels of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  products</td>
    </tr>
    <tr>
      <td>In Japan, customers are reimbursed     for <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">products under</font> a <font color="blue">government</font>-operated insurance     system</td>
    </tr>
    <tr>
      <td>Under this system, the Japanese <font color="blue">government</font> annually reviews the     <font color="blue">reimbursement</font>  levels  for  products</td>
    </tr>
    <tr>
      <td><font color="blue">The Japanese </font><font color="blue">government</font> is also     considering other <font color="blue">reimbursement</font> regulation</td>
    </tr>
    <tr>
      <td><font color="blue">If the Japanese </font><font color="blue">government</font>     decides to reduce <font color="blue">reimbursement</font> levels for <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>products,     its <font color="blue">product pricing may</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is, or may be, subject to lawsuits related to products     or services <font color="blue">manufacture</font>d or performed by the Company</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is, or may be, a party to, or may be otherwise     responsible for, pending or <font color="blue">threatened lawsuits</font> or other claims related to     products and <font color="blue">services currently</font> or formerly <font color="blue">manufacture</font>d or performed, as     applicable, by the Company</td>
    </tr>
    <tr>
      <td>Such cases and claims may raise <font color="blue">difficult</font> and     complex factual and <font color="blue">legal issues</font> and may be subject to many <font color="blue">uncertainties</font>     and <font color="blue">complexities</font>, including, but not limited to, the facts and <font color="blue">circumstances</font>     of <font color="blue">each particular case</font> or claim, the <font color="blue">jurisdiction</font> in <font color="blue">which each suit</font> is     brought, and <font color="blue">differences</font> in <font color="blue">applicable law</font></td>
    </tr>
    <tr>
      <td>Upon resolution of any such     <font color="blue">legal matters</font> or other claims, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">may incur charges</font> in     excess of <font color="blue">established reserves</font></td>
    </tr>
    <tr>
      <td>While any such charge could have a material     <font color="blue">adverse impact on</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  net income or <font color="blue">net cash flows</font> in the     period in which it is recorded or paid, <font color="blue">management</font> believes that no such     charge relating to any <font color="blue">currently pending lawsuit would</font> have a material     adverse effect on <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">financial position</font>, results of     <font color="blue">operations</font> or liquidity</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue"><font color="blue">may incur increased</font> costs as</font> a result of recent changes     in laws and <font color="blue">regulations</font> affecting public companies</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with changes in laws and <font color="blue">regulations</font> affecting public     <font color="blue">companies such as</font> the Sarbanes-Oxley Act of 2002 requiring an <font color="blue">evaluation</font> of     the <font color="blue">effectiveness</font> of internal controls over financial reporting may result     in  increased  <font color="blue">accounting</font>, legal and <font color="blue">administrative</font> costs</td>
    </tr>
    <tr>
      <td>The cost of     <font color="blue">complying with</font> these <font color="blue">requirements</font> is substantial and <font color="blue">could increase</font> in the     future</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue"><font color="blue">common stock</font> may</font> be volatile</td>
    </tr>
    <tr>
      <td>The  market  price of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue"><font color="blue">common stock</font> could</font>     fluctuate <font color="blue">substantially</font> in the future in response to any of the other risk     factors  set out above and below as well as a number of other factors,     including the following:          •                 quarterly variations in operating results, <font color="blue">as discussed</font> above                 under   &amp;quote —<font color="blue">Fluctuations  </font>in  <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  quarterly                 operating results may cause its stock price to decline; &amp;quote           •                 <font color="blue">announcements</font>  of  <font color="blue">innovations</font>,  new  products,  strategic                 <font color="blue">development</font>s or business <font color="blue">combination</font>s by <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>or                 its <font color="blue">competitors</font>;                                         17       _________________________________________________________________       •            changes in <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>expected operating <font color="blue">expense levels</font> or            income and losses;     •            changes in financial estimates and <font color="blue">recommendations</font> of securities            analysts;     •            the operating and <font color="blue">securities price performance</font> of other companies            that <font color="blue">investors may</font> deem comparable to <font color="blue">Edwards Lifesciences</font>; and     •            changes in general <font color="blue">conditions</font> in the economy, the <font color="blue">financial markets</font>,            the domestic or <font color="blue">international political</font> situation or the medical            device industry</td>
    </tr>
    <tr>
      <td>In  addition, in <font color="blue">recent years</font> the <font color="blue">stock market</font> has experienced     <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font>     effect on the <font color="blue">market price</font>s of <font color="blue">securities issued by</font> many companies for     reasons  unrelated  to their operating performance</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font>     <font color="blue">fluctuations</font> may <font color="blue">materially</font> <font color="blue">adversely</font> affect <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  stock     price, regardless of its operating results</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">stockholder rights</font> plan, charter and bylaws, as well     <font color="blue">as provisions</font> of <font color="blue">Delaware </font>law, the change in control provisions of the     3dtta875prca convertible senior <font color="blue">debentures</font> issued by <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>and the     change  in  control  provisions  of  other <font color="blue">agreements</font> to which Edwards     <font color="blue">Lifesciences </font> is a party, could make it <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire the Company</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has a <font color="blue">stockholder rights</font> plan that may have the     effect of <font color="blue">discouraging unsolicited takeover proposals</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">rights issued</font>     under the <font color="blue">stockholder rights</font> plan would cause substantial dilution to a     person or group that attempts to acquire <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>on terms not     approved  in  <font color="blue">advance by</font> its board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Delaware </font>    corporate  law  and  Edwards  <font color="blue">Lifesciences </font>&amp;apos  charter and <font color="blue">bylaws contain</font>     provisions that could delay, deter or prevent a change in control of the     Company or its <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could also discourage proxy</font>     contests and make it more <font color="blue">difficult</font> for <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">stockholders</font>     to elect <font color="blue">directors</font> and take other <font color="blue">corporate actions without</font> the <font color="blue">concurrence</font>     of its <font color="blue">management</font> or board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions:          •                 authorize <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  board of <font color="blue">directors</font> to issue                  &amp;quote blank check &amp;quote  <font color="blue">preferred stock</font>, which is <font color="blue">preferred stock</font> that can                 be  created  and issued by its board of <font color="blue">directors</font>, without                 stockholder approval, with rights senior to those of common                 stock;          •                 provide for a <font color="blue">staggered board</font> of <font color="blue">directors</font> and three-year terms                 for  <font color="blue">directors</font>, so that no more than a minority of Edwards                 <font color="blue">Lifesciences </font>&amp;apos  <font color="blue">directors</font> could be <font color="blue">replaced at</font> any <font color="blue">annual meeting</font>;          •                 provide that <font color="blue">directors</font> may be <font color="blue">removed only</font> for cause;          •                 provide that <font color="blue">stockholder action may</font> be <font color="blue">taken only at</font> a special                 or <font color="blue">regular meeting</font> and not <font color="blue">by written consent</font>;          •                 provide  for  super  majority voting <font color="blue">requirements</font> for some                 provisions of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  charter; and          •                 <font color="blue">establish advance</font> notice <font color="blue">requirements</font> for <font color="blue">submitting nominations</font>                 for election to the board of <font color="blue">directors</font> and for <font color="blue">proposing matters</font>                 to be acted upon by <font color="blue">stockholders</font> at a meeting</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>is also subject to anti-takeover provisions     under <font color="blue">Delaware </font>law, <font color="blue">which could</font> also delay or prevent a change of control</td>
    </tr>
    <tr>
      <td>Together, these provisions of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  charter and bylaws,     <font color="blue">Delaware </font>law and its <font color="blue">stockholder rights</font> plan <font color="blue">may discourage <font color="blue">transaction</font>s</font>     that <font color="blue">otherwise could provide</font> for the payment of a <font color="blue">premium over prevailing</font>     <font color="blue">market price</font>s of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">common stock</font>, and <font color="blue">also could limit</font>     the price that investors are willing to pay in the future for shares of its     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>undergoes a change in control     (as  defined in the indenture relating to <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  3dtta875prca     convertible senior <font color="blue">debentures</font>) prior to May 15, 2008, the holders of the     3dtta875prca convertible senior <font color="blue">debentures</font> have the right, at their option, to     require <font color="blue">Edwards                                         </font>18       _________________________________________________________________       <font color="blue">Lifesciences </font>to purchase all or a portion of the <font color="blue">debentures</font> they hold</td>
    </tr>
    <tr>
      <td>In     addition, certain change in <font color="blue">control events</font> relating <font color="blue">to the Company</font> may     <font color="blue">constitute</font> or otherwise result in events of <font color="blue">default under</font> the Companyapstas     other <font color="blue">debt <font color="blue">instruments</font></font> or its <font color="blue">receivables</font> <font color="blue">facilities</font>, <font color="blue">which could</font> result in     <font color="blue">borrowings</font> outstanding and other <font color="blue">amounts due under</font> those <font color="blue">debt <font color="blue">instruments</font></font>     and <font color="blue">receivables</font> <font color="blue">facilities</font> becoming immediately due and payable</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>features of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  3dtta875prca convertible senior <font color="blue">debentures</font> and     other <font color="blue">debt <font color="blue">instruments</font></font> and <font color="blue">receivables</font> <font color="blue">facilities</font>, and features of Edwards     <font color="blue">Lifesciences </font>&amp;apos  <font color="blue">employee equity programs</font> and change in <font color="blue">control severance</font>     <font color="blue">agreements</font> with the Companyapstas <font color="blue">executive officers which</font> have the effect of     <font color="blue">accelerating vesting</font> of <font color="blue">equity awards</font> or causing <font color="blue">severance payments</font> to     become  due  and payable, may also discourage a person or a group from     attempting to acquire <font color="blue">Edwards Lifesciences</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  issuance of <font color="blue">preferred stock</font> <font color="blue">could <font color="blue">adversely</font></font> affect     holders of its <font color="blue">common stock</font> and discourage a takeover</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  board of <font color="blue">directors</font> is authorized to issue up     to 50cmam000cmam000 shares of <font color="blue">preferred stock</font> without any <font color="blue">action on</font> the part of     its <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  board of <font color="blue">directors</font> also has the     power, without stockholder approval, to set the terms of any series of     preferred  stock that may be issued, including voting rights, dividend     rights, <font color="blue">preferences</font> over its <font color="blue">common stock</font> with respect to dividends or in     the event of a dissolution, liquidation or <font color="blue">winding up</font> and other terms</td>
    </tr>
    <tr>
      <td>In     the event that <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>issues <font color="blue">preferred stock</font> in the future     that  has  <font color="blue">preference over</font> its <font color="blue">common stock</font> with respect to payment of     dividends or upon its liquidation, dissolution or <font color="blue">winding up</font>, or if Edwards     <font color="blue">Lifesciences </font>issues <font color="blue">preferred stock</font> with voting rights that dilute the     <font color="blue">voting power</font> of its <font color="blue">common stock</font>, the rights of the holders of its common     stock or the <font color="blue">market price</font> of its <font color="blue"><font color="blue">common stock</font> could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition, the ability of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  board of <font color="blue">directors</font> to     issue  shares of <font color="blue">preferred stock</font> without any <font color="blue">action on</font> the part of its     <font color="blue">stockholders</font> may impede a takeover of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>and prevent a     <font color="blue">transaction</font> favorable to the holders of its <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Recent changes related to equity compensation <font color="blue">could <font color="blue">adversely</font></font> affect Edwards     <font color="blue">Lifesciences </font>&amp;apos  ability to attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Since inception, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>has <font color="blue">used <font color="blue"><font color="blue">stock option</font>s</font></font> and     other long-term equity based incentives as a <font color="blue">fundamental</font> component of its     <font color="blue">employee compensation packages</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that <font color="blue"><font color="blue">stock option</font>s</font> and     other long-term equity based incentives directly motivate employees to     maximize  long-term stockholder value and, through the use of vesting,     <font color="blue">encourage employees</font> to <font color="blue">remain with</font> the Company</td>
    </tr>
    <tr>
      <td>The Financial Accounting     Standards Board issued changes to the <font color="blue"><font color="blue">United States</font> </font><font color="blue">generally</font> accepted     <font color="blue">accounting</font> principles that require <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>to record a charge     to earnings for new and unvested <font color="blue"><font color="blue">stock option</font>s</font> beginning January 1, 2006</td>
    </tr>
    <tr>
      <td>In     addition, increased investor interest in equity-based compensation and New     York Stock Exchange <font color="blue">rules prohibiting</font> NYSE member <font color="blue">organizations</font> from voting     on equity-based compensation plans unless the <font color="blue">beneficial owner</font> of the shares     has given express <font color="blue">voting instructions could</font> make it more <font color="blue">difficult</font> for the     Company to obtain approval of future <font color="blue">stock option</font> grants to employees</td>
    </tr>
    <tr>
      <td>To     the extent that these changes make it more <font color="blue">difficult</font> or expensive to grant     stock  options  to employees, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font><font color="blue">may incur increased</font>     <font color="blue">compensation costs</font>, change its <font color="blue">equity compensation strategy</font> or find it     <font color="blue">difficult</font> to attract, retain and motivate employees, each of <font color="blue">which could</font>     <font color="blue">materially</font> <font color="blue">adversely</font> affect the Company</td>
    </tr>
    <tr>
      <td>Future sales of <font color="blue">common stock</font> in the <font color="blue">public market</font> <font color="blue">could <font color="blue">adversely</font></font> affect the     <font color="blue">trading price</font> of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos  <font color="blue">common stock</font> and its ability to raise     funds in <font color="blue">new securities offerings</font></td>
    </tr>
    <tr>
      <td>Future sales of substantial amounts of the <font color="blue">common stock</font> of Edwards     <font color="blue">Lifesciences </font>in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that <font color="blue">such sales could</font>     occur, <font color="blue">could <font color="blue">adversely</font></font> affect prevailing <font color="blue">trading price</font>s of the <font color="blue">common stock</font>     of <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>that it may issue and <font color="blue">could impair</font> its ability to     <font color="blue">raise capital</font>                                         19       _________________________________________________________________       <font color="blue">through future offerings</font> of equity or equity-related securities</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>had:          •                 59cmam524cmam866 shares of <font color="blue">common stock</font> outstanding;          •                 10cmam253cmam574 shares of <font color="blue">common stock</font> reserved for <font color="blue">issuance upon</font>                 exercise of <font color="blue">options outstanding under</font> <font color="blue"><font color="blue">Edwards Lifesciences</font> </font>&amp;apos                  <font color="blue">stock option</font> plans with a <font color="blue">weighted average exercise price</font> of                 dlra27dtta62 per share;          •                 2cmam088cmam850 shares of <font color="blue">common stock</font> reserved for <font color="blue">future issuance</font>                 under  incentive  <font color="blue">compensation programs</font> and <font color="blue">employee stock</font>                 purchase plans; and          •                 2cmam744cmam238 shares of <font color="blue">common stock</font> reserved for <font color="blue">issuance upon</font>                 <font color="blue">conversion</font>  of  Edwards  <font color="blue">Lifesciences </font>&amp;apos   outstanding 3dtta875prca                 convertible senior <font color="blue">debentures</font></td>
    </tr>
    <tr>
      <td>No prediction can be made as to the effect, if any, that future     issuances of shares of <font color="blue">common stock</font> or the <font color="blue">availability</font> of shares of common     stock for future sale, will have on the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Issuances </font>of substantial amounts of <font color="blue">common stock</font>, or the <font color="blue">perception</font> that     <font color="blue">such issuances could</font> occur, may <font color="blue">adversely</font> affect prevailing <font color="blue">market price</font>s     for our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>